Skip to main content
Premium Trial:

Request an Annual Quote

Roche Proposes Nominees for Ventana's Board of Directors

NEW YORK (GenomeWeb News) - In another strategic move in its attempt to acquire Ventana Medical Systems, Roche plans to nominate four independent candidates for Ventana’s board of directors, Roche said in a statement yesterday.
Roche also hopes to change Ventana’s bylaws to remove its classified board and reduce its number of directors from 10 to seven.
Roche has renewed several times a bid to take over Ventana for $75 a share, or around $3 billion, which was a 55 percent premium over Ventana’s value over the three months before the late-June offer.
After vehemently rejecting the offer as inadequate, due to some expectations Ventana has about its future prospects and its “synergistic value to Roche,” the company agreed last month to open its books to show why it believes Roche’s offer undervalues the company.
"We have taken this step, as required by Ventana's bylaws, because we are committed to pursuing the acquisition of Ventana,“ said Roche CEO and Chairman Franz Humer. “However, we continue to prefer a negotiated transaction."
Roche said it plans to nominate Dwight Crane, John Jones, Loring Knoblauch, and Michael Kranda to Ventana’s board of directors. If Ventana’s shareholders elect these nominees and agree to the proposed changes in bylaws, Roche also would nominate Bary Bailey, Jay Hunt, and Anthony Wild to fill the remaining three seats on the board.
Ventana’s shares were trading at $89 on the Nasdaq early Thursday.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.